Wilex is a biopharmaceutical company focused on oncology and antibodies. The parent company WILEX AG no longer pursues clinical development activities in Munich, instead acting exclusively as a holding company. Operation concentrate on the research and development activities of the subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma workes with the toxin Amanitin and an ADC technology with the goal of coupling this highly effective agent with various antibodies to make it usable for treating cancer. This innovative technology platform is progressively being developed for therapeutic antibody drug conjugates for use in proprietary projects and partnerships.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
DGAP-News: Heidelberg Pharma AG / Schlagwort(e): Sonstiges Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA 07.09.2021 / 07:21 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Heidelberg Pharma gibt Update zur klinischen Phase I/IIa-Studie mit dem ATAC-Kandidaten HDP-101 in den USA - Kompatibilitätstests für geschlossenes Infusionssystem mit HDP-101 erfolgreich abgeschlossen- Versand der Studienmedikation in die USA in Vorbereitung- Vertrag mit erstem Studienzentrum, ...
DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US 07.09.2021 / 07:21 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the US - Compatibility tests for closed infusion system with HDP-101 successfully completed- Shipping of study medication to the US in preparation- Contract signed with first study center, MD Anderson Cancer Ce...
HEIDELBERG PHARMA - BUY | EUR12 (+60%) H1 2021 brings closer to value inflection point Phase I/II study of HDP-101 is now expected to start recruitment in Q3 Partners are moving along with ATACs development Reiterating BUY rating and TP EUR12
VIVENDI - NEUTRAL | EUR29.3(-10%) Full takeover might not be the best scenario Buy out of Amber’s stake leads to possible takeover More than decent price, yet premium not overwhelming The interest of a full takeover at this price is not obvious Synergies potential limited with Travel retail as a burden
SENSORION - CORPORATE | EUR6(+192%) Sensorion and Sonova sign strategic research collaboration A multi-year strategic collaboration A natural history study at the heart of this partnership A NHS provides critical information for rare and orphan diseases Once again confirms Sensorion’s leadership in hearing loss
INDITEX - BUY | EUR33(+12%) H1 2021 results: Top line is recovering a bit faster than margins Q2 sales matched CS forecasts: a good top-line recovery Q2 GM and EBIT a touch shy of CS expectations Declining inventory levels towards healthier levels Encouraging current trading: sales between 1st Aug – 9th Sep: +22%
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.